Antibody induction therapy for lung transplant recipients

  • Protocol
  • Intervention

Authors

  • Luit Penninga,

    Corresponding author
    1. Rigshospitalet, Copenhagen University Hospital, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Dept 3344 & Surgery and Transplantation, Dept C2122, Copenhagen, Denmark
    • Luit Penninga, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Dept 3344 & Surgery and Transplantation, Dept C2122, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. LP@ctu.rh.dk. luitpenninga@hotmail.com.

    Search for more papers by this author
  • Christian H Møller,

    1. Copenhagen University Hospital, Dept 2152, Copenhagen Trial Unit, Copenhagen, Denmark
    Search for more papers by this author
  • Elisabeth I Penninga,

    1. Bispebjerg Hospital, Department of Clinical Pharmacology, Copenhagen, Denmark
    Search for more papers by this author
  • Martin Iversen,

    1. Copenhagen University Hospital Rigshospitalet, Medical Department B-2142, Division of Lung Transplantation, Copenhagen, Denmark
    Search for more papers by this author
  • Christian Gluud,

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author
  • Daniel A Steinbrüchel

    1. Rigshospitalet, Copenhagen University Hospital, Dept 2152, Cardiothoracic Surgery, Copenhagen, Denmark
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

This review aims to assess the benefits and harms of immunosuppressive antibody induction therapy with ATG, ALG, IL2Ra, alemtuzumab, or muromonab-CD3 for lung transplant recipients.

Ancillary